Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 148 of the 148 references it cites were found in a registry or an index.

20-Hydroxyecdysone, from Plant Extracts to Clinical Use: Therapeutic Potential for the Treatment of Neuromuscular, Cardio-Metabolic and Respiratory Diseases

Open access
Dinan, Laurence, Dioh, Waly, Veillet, Stanislas, Lafont, Rene · 2021 · Biomedicines

Abstract

There is growing interest in the pharmaceutical and medical applications of 20-hydroxyecdysone (20E), a polyhydroxylated steroid which naturally occurs in low but very significant amounts in invertebrates, where it has hormonal roles, and in certain plant species, where it is believed to contribute to the deterrence of invertebrate predators. Studies in vivo and in vitro have revealed beneficial effects in mammals: anabolic, hypolipidemic, anti-diabetic, anti-inflammatory, hepatoprotective, etc. The possible mode of action in mammals has been determined recently, with the main mechanism involving the activation of the Mas1 receptor, a key component of the renin–angiotensin system, which would explain many of the pleiotropic effects observed in the different animal models. Processes have been developed to produce large amounts of pharmaceutical grade 20E, and regulatory preclinical studies have assessed its lack of toxicity. The effects of 20E have been evaluated in early stage clinical trials in healthy volunteers and in patients for the treatment of neuromuscular, cardio-metabolic or respiratory diseases. The prospects and limitations of developing 20E as a drug are discussed, including the requirement for a better evaluation of its safety and pharmacological profile and for developing a production process compliant with pharmaceutical standards.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/biomedicines9050492

Cites

148 of 148 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 20-hydroxyecdysone (20E; β-ecdysone; crustecdysone; ecdysterone; BIO101; CAS 5289-74-7; IUPAC 2β,3β,14α,20R,22R,25-hexahydroxy-5β-cholest-7-en-6-one).
Figure 1 20-hydroxyecdysone (20E; β-ecdysone; crustecdysone; ecdysterone; BIO101; CAS 5289-74-7; IUPAC 2β,3β,14α,20R,22R,25-hexahydroxy-5β-cholest-7-en-6-one).CC BY · PubMed Central
Figure 2 (A) The effects of 20E (0.01–10 μM) on protein synthesis in C2C12 cells, showing the anabolic effect of 20E on optimal value for 1 µM 20E. C2C12 cells were grown on 24-well plates at a density of 30,000 cells/well in 0.5 mL of growth medium (Dulbecco’s Modified Eagle Medium (DMEM) 4.5 g/L glucose supplemented with 10% fetal bovine serum). Twenty-four hours after plating, the differentiation induction into multinucleated myotubes was carried out, and after 5 days, cells were pre-incubated in Krebs medium 1 h at 37 °C before being incubated in DMEM media without serum for 2.5 h in the presence of [3H]-Leucine (5 µCi/mL) and DMSO (control condition) or IGF-1 (100 ng/mL) or 20E (0.01–0.1–1–10 µM). At the end of incubation, supernatants were discarded and cells were lysed in 0.1 N NaOH for 30 min. The cell soluble fraction-associated radioactivity was then counted and protein was quantified using the Lowry method (after [103]). (B) Effects of dexamethasone (Dexa 6 = 10−6 M, Dexa 5 = 10−5 M), IGF-1 (10 ng/mL), and 20E (10−6 M) on the diameter of C2C12 myotubes. Four- to six-day-old myotubes were incubated for 48 h with test chemicals, and were fixed and photographed by glutaraldehyde-induced autofluorescence. *: p = < 0.05; **: p = 0.01. (redrawn and modified from [54]).
Figure 2 (A) The effects of 20E (0.01–10 μM) on protein synthesis in C2C12 cells, showing the anabolic effect of 20E on optimal value for 1 µM 20E. C2C12 cells were grown on 24-well plates at a density of 30,000 cells/well in 0.5 mL of growth medium (Dulbecco’s Modified Eagle Medium (DMEM) 4.5 g/L glucose supplemented with 10% fetal bovine serum). Twenty-four hours after plating, the differentiation induction into multinucleated myotubes was carried out, and after 5 days, cells were pre-incubated in Krebs medium 1 h at 37 °C before being incubated in DMEM media without serum for 2.5 h in the presence of [3H]-Leucine (5 µCi/mL) and DMSO (control condition) or IGF-1 (100 ng/mL) or 20E (0.01–0.1–1–10 µM). At the end of incubation, supernatants were discarded and cells were lysed in 0.1 N NaOH for 30 min. The cell soluble fraction-associated radioactivity was then counted and protein was quantified using the Lowry method (after [103]). (B) Effects of dexamethasone (Dexa 6 = 10−6 M, Dexa 5 = 10−5 M), IGF-1 (10 ng/mL), and 20E (10−6 M) on the diameter of C2C12 myotubes. Four- to six-day-old myotubes were incubated for 48 h with test chemicals, and were fixed and photographed by glutaraldehyde-induced autofluorescence. *: p = < 0.05; **: p = 0.01. (redrawn and modified from [54]).CC BY · PubMed Central
Figure 3 Dose-dependent inhibition of myostatin gene expression in C2C12 cells by 20E. C2C12 mouse myoblasts were differentiated for 6 days into myotubes. They were then treated for 6 h with concentrations of 20E ranging from 0.001 to 10 μM. Myostatin gene expression was detected by qRT-PCR. Results are shown as means ± standard error of the mean (SEM) ([103]).
Figure 3 Dose-dependent inhibition of myostatin gene expression in C2C12 cells by 20E. C2C12 mouse myoblasts were differentiated for 6 days into myotubes. They were then treated for 6 h with concentrations of 20E ranging from 0.001 to 10 μM. Myostatin gene expression was detected by qRT-PCR. Results are shown as means ± standard error of the mean (SEM) ([103]).CC BY · PubMed Central
Figure 4 Effect of 20E on mice fed a high-fat diet (HF), when compared to mice fed a low-fat diet (LF). The animals received either pure 20E (50 mg/kg/day) or the same amount of 20E as a quinoa extract (Q). Panel (A) shows the impact on the mass of epididymal adipose tissue (*** p < 0.01 when compared to LF; ## p < 0.01 and ### p < 0.001 when compared to HF) and panel (B) shows the effect on adipocyte diameter (reproduced, with permission, from [59]).
Figure 4 Effect of 20E on mice fed a high-fat diet (HF), when compared to mice fed a low-fat diet (LF). The animals received either pure 20E (50 mg/kg/day) or the same amount of 20E as a quinoa extract (Q). Panel (A) shows the impact on the mass of epididymal adipose tissue (*** p < 0.01 when compared to LF; ## p < 0.01 and ### p < 0.001 when compared to HF) and panel (B) shows the effect on adipocyte diameter (reproduced, with permission, from [59]).CC BY · PubMed Central
Figure 5 20E reduction of myostatin gene expression in C2C12 cells (differentiated for 6 days into myotubules) is mediated by binding to receptor sites on the external surface of the cells. The histogram compares the activities of IGF-1 (100 nM) and 20E (10 μM) with those of conjugates of 20E covalently bound to protein (HSA or BSA) through different C-atoms (C-2 and C-22-hemisuccinates or C-6 [6-carboxymethoxime]), all at nominal 10 μM hapten concentration. BSA bovine serum albumin; HSA: human serum albumin; error bars = standard error of the mean [103,114].
Figure 5 20E reduction of myostatin gene expression in C2C12 cells (differentiated for 6 days into myotubules) is mediated by binding to receptor sites on the external surface of the cells. The histogram compares the activities of IGF-1 (100 nM) and 20E (10 μM) with those of conjugates of 20E covalently bound to protein (HSA or BSA) through different C-atoms (C-2 and C-22-hemisuccinates or C-6 [6-carboxymethoxime]), all at nominal 10 μM hapten concentration. BSA bovine serum albumin; HSA: human serum albumin; error bars = standard error of the mean [103,114].CC BY · PubMed Central
Figure 6 Diagrammatic representation of the proposed mode of action of 20E in the regulation of protein synthesis in C2C12 muscle cells in vitro ([113]).
Figure 6 Diagrammatic representation of the proposed mode of action of 20E in the regulation of protein synthesis in C2C12 muscle cells in vitro ([113]).CC BY · PubMed Central
Figure 7 Time-course of the distribution of radioactivity in the stomach/intestine/feces in mice after the oral application of [1α,2α-3H2]20E. Note the logarithmic scale for abscissa. Each value is a mean of 2 animals. Note the plateau of small intestine content that is best explained by an entero-hepatic cycle and consistent with the prolonged concentration of radioactivity in bile as observed by Wu et al. [124] (reproduced, with permission, from [127]).
Figure 7 Time-course of the distribution of radioactivity in the stomach/intestine/feces in mice after the oral application of [1α,2α-3H2]20E. Note the logarithmic scale for abscissa. Each value is a mean of 2 animals. Note the plateau of small intestine content that is best explained by an entero-hepatic cycle and consistent with the prolonged concentration of radioactivity in bile as observed by Wu et al. [124] (reproduced, with permission, from [127]).CC BY · PubMed Central
Figure 8 Comparison of the temporal (A) and cumulative (B) urinary and fecal elimination of radioactivity after the oral application of [5,7,9-3H]20E to 6–7 week-old male Wistar rats. After oral application of [3H]20E, elimination of radioactively labelled 20E and its metabolites is completed within 48 h. The amount of radioactivity recovered from the feces is by far the major route of excretion, since the amount in the urine corresponds to only 1.40% of the total radioactivity recovered. (Reproduced, with permission, from [127]).
Figure 8 Comparison of the temporal (A) and cumulative (B) urinary and fecal elimination of radioactivity after the oral application of [5,7,9-3H]20E to 6–7 week-old male Wistar rats. After oral application of [3H]20E, elimination of radioactively labelled 20E and its metabolites is completed within 48 h. The amount of radioactivity recovered from the feces is by far the major route of excretion, since the amount in the urine corresponds to only 1.40% of the total radioactivity recovered. (Reproduced, with permission, from [127]).CC BY · PubMed Central
Figure 9 Pharmacokinetics of 20E in young and elderly humans given a single dose of 1400 mg. 20E was quantified by HPLC-MS [136,137].
Figure 9 Pharmacokinetics of 20E in young and elderly humans given a single dose of 1400 mg. 20E was quantified by HPLC-MS [136,137].CC BY · PubMed Central
Figure 10 The principal routes of metabolism of 20E in rodents and humans (modified from Kumpun et al., 2011). The circles and arrows in red highlight the changes associated with 14-dehydroxylation, while the boxes and arrows in blue highlight the changes associated with side-chain cleavage.
Figure 10 The principal routes of metabolism of 20E in rodents and humans (modified from Kumpun et al., 2011). The circles and arrows in red highlight the changes associated with 14-dehydroxylation, while the boxes and arrows in blue highlight the changes associated with side-chain cleavage.CC BY · PubMed Central
Figure 11 A representative flow-diagram for the large-scale extraction and purification of 20E from roots of Cyanotis sp.
Figure 11 A representative flow-diagram for the large-scale extraction and purification of 20E from roots of Cyanotis sp.CC BY · PubMed Central
Figure 12 SARS-CoV-2 infection will result in a strong impairment of the activity of angiotensin converting enzyme 2 (ACE2), hence a lack of angiotensin-(1-7) production and a disequilibrium between the harmful and protective arms of the renin–angiotensin system (RAS). Treatment with BIO101 (20E) is expected to activate Mas receptor and the protective arm of RAS, thus preventing inflammation and lung damage.
Figure 12 SARS-CoV-2 infection will result in a strong impairment of the activity of angiotensin converting enzyme 2 (ACE2), hence a lack of angiotensin-(1-7) production and a disequilibrium between the harmful and protective arms of the renin–angiotensin system (RAS). Treatment with BIO101 (20E) is expected to activate Mas receptor and the protective arm of RAS, thus preventing inflammation and lung damage.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

13 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 148 references

Research works printed but not linked: 22

  1. Koolman, J. (1989). Ecdysone: From Chemistry of Mode of Action, Thieme Verlag.
  2. Koolman, J. (1989). Strategies for the synthesis of ecdysteroids. Ecdysone. From Chemistry to Mode of Action, Thieme Verlag.
  3. Fernández, H. (2011). Ferns: From traditional uses to pharmacological development, chemical identification of active principles. Working with Ferns: Issues and Applications, Springer Science+Business Media B.V.
  4. Zou, 2008, Advances in pharmacological research on ecdysteroids, Zhongguo Xinyao Zazhi, 17, 371
  5. Song, 2019, Protective effect of 20-hydroxy-ecdysterone against lipopolysaccharides-induced acute lung injury in mice, J. Pharm. Drug Res., 2, 109
  6. Luo, 2009, Effect of ecdysterone on injury of lipid peroxidation following focal cerebral ischemia in rats, Zhongguo Yaoye, 18, 12
  7. Xia, 2013, Protective effect of 20-hydroxyecdysone on diabetic hepathopathy of rats, Xiandai Yufang Yixue, 40, 4031
  8. Wu, 1998, Effects of ecdysterone on rat lung reperfusion injury, Chin. Pharm. Bull., 14, 256
  9. Zou, 2010, Effects of ecdysterone on early stage diabetic nephropathy in streptozotocin-induced diabetic rats, Chin. J. New Drugs Clin. Remedies, 29, 842
  10. Detmar, 1994, Effects of ecdysterone on the differentiation of normal keratinocytes in vitro, Eur. J. Dermatol., 4, 558
  11. Dilda, 2016, BIO101, a drug candidate targeting Mas receptor for the treatment of age-reated muscle degeneration. From molecular target identification to clinical development, J. Cachexia Sarcopenia Muscle, 7, 655
  12. Lupien, 1969, Ecdysterone as a hypoholesterolemic agent, Arch. Int. Physiol. Biochim., 77, 206
  13. Raynal, 2015, BIO101, a drug candidate targeting sarcopenic obesity through MAS receptor activation, J. Cachexia Sarcopenia Muscle, 6, 429
  14. Koolman, J. (1989). Ecdysteroids in vertebrates: Pharmalogical aspects. Ecdysone—from Chemistry to Mode of Action, Georg Thieme Verlag.
  15. Simon, P. (1988). Ecdysteroids in the mammalian organism and their detection as a means of diagnosis antihelmintic infections (Ecdysteroide im Säugerorganismus und ihr Nachweis als Möglichkeit der Diagnose helmintischer Infektionen). [Ph.D. Thesis, University of Marburg].
  16. Bolduc, T.M. (2008). Human Urinary Excretion Profiles after Exposure to ecdysterone. [Master’s Thesis, University of Utah].
  17. Brandt, W. (2003). Pharmakokinetik und Metabolismus des 20-Hydroxyecdysons im Menschen. [Ph.D. Thesis, Marburg].
  18. Wang, 1996, The dynamic variations of 20-hydroxyecdysone in Cyanotis arachnoidea, Acta Bot. Yunnanica, 18, 459
  19. Volodin, 2006, Pharmacological estimate of new ecdysteroid-containing substance “Serpisten”, Rastit Resur., 42, 113
  20. Martnussen, 2011, Effect of climate on plant growth and level od adaptogenic compounds in Maral root (Leuzea carthamoides Willd., DC), crowned saw-wort (Serratula coronata L.) and roseroot (Rhodiola rosea L.), Eur. J. Plant. Sci. Biotechnol., 5, 72
  21. Mirzaev, 2000, Study of the effects of ecdysten on the sexual function under experimental and clinical conditions, Eksp. Klin. Farm., 63, 35
  22. Thole, S.W. (2018). The Metabolic Syndrome: The Effects of β-ecdysone on Selected Body Parameters and Serum Lipids on the Metabolic Syndrome. [Ph.D. Thesis, University of Göttingen].

Cited by

See all 99

Metadata

Authors
Dinan, L., Dioh, W., Veillet, S., & Lafont, R.
Affiliations
  • Sorbonne Université (FR)
  • Biophytis, Sorbonne Université, BC9, 4 place Jussieu, 75005 Paris, France
Venue
Biomedicines
Publisher
MDPI AG
Published
2021-04-29
Volume
9
Issue
5
Pages
492
ISSN
2227-9059 (ISSN-L)
OpenAlex
W3157948752
Cited by
99
References
148
Citations by year
2026: 17 · 2025: 21 · 2024: 22 · 2023: 21 · 2022: 12 · 2021: 6
FWCI
1.60
Type
journal article
Language
en
Open access
Locations
  • Biomedicines (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • Oskar-Bordeaux (Universite de Bordeaux) (submittedVersion)
Topics
  • Physical Sciences › Chemistry › Organic Chemistry › Phytochemical Studies and Bioactivities
  • Physical Sciences › Chemistry › Organic Chemistry › Steroid Chemistry and Biochemistry
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Keywords
20-hydroxyecdysone, polyhydroxylated steroids, renin-angiotensin system, hypolipidemic effect, anti-diabetic effects, anti-inflammatory activity, hepatoprotection, neuromuscular disorders, cardiometabolic disease, respiratory diseases, plant extracts, pharmaceutical manufacturing, drug development, clinical trials

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 20-Hydroxyecdysone, from Plant Extracts to Clinical Use: Therapeutic Potential for the Treatment of Neuromuscular, Cardio-Metabolic and Respiratory Diseases. https://app.cochat.ai/papers/10.3390/biomedicines9050492
The paper
Dinan, L., Dioh, W., Veillet, S., & Lafont, R. (2021). 20-Hydroxyecdysone, from Plant Extracts to Clinical Use: Therapeutic Potential for the Treatment of Neuromuscular, Cardio-Metabolic and Respiratory Diseases. Biomedicines. https://doi.org/10.3390/biomedicines9050492

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.